The rationale behind most genetic studies of psychiatric disease is to provide a causal mechanistic basis for the development of effective therapies 1, 2 . However, this approach faces challenges at many levels, from the identification of bona fide risk genes, to modeling their effects in experimental systems, to translating experimental findings from these systems to focused human subject research, and eventually to the identification of targets with clinical utility. The advent of genome-wide association studies (GWAS) using high-density genotyping of single-nucleotide polymorphisms (SNPs) made it possible to scan large populations of affected individuals (cases) and controls to identify common genetic variants associated with common diseases. Once it became clear that enormous sample sizes were necessary to detect the relatively small effect sizes of common alleles, major collaborative efforts in psychiatric disease were initiated. For schizophrenia, this effort recently culminated in the identification of over 100 loci contributing to schizophrenia, a major milestone in the field 3 . The hope is that each of these hundred loci will guide us to the underlying gene or variant driving the disease association and that, when pieced together, these findings will expose the pathophysiological mechanisms of schizophrenia. A recent study published in Nature by Sekar et al. 4 takes this first critical step by identifying the functional alleles driving the signal in the most significantly associated schizophrenia GWAS locus, which lies within the major histocompatibility complex (MHC) locus on chromosome 6 (Fig. 1) .
The MHC spans ~4 Mb and is one of the most gene-dense regions of the genome. It contains genes that function in the acquired immune system, including 18 highly polymorphic human leukocyte antigen (HLA) genes. The prospect of identifying the functional alleles driving this MHC association is daunting for two main reasons: (i) the MHC is highly polymorphic and has many repetitive sequences and extensive linkage disequilibrium (large regions co-inherited as blocks) and (ii) the pattern of schizophrenia-associated markers is complex, with multiple associated markers in close proximity to hundreds of genes 3 . Given that the strongest association within the MHC lies near the complement component 4 (C4) genes and that a genomewide significant association on chromosome 8 lies near CSMD1 (ref. 3) , which encodes a protein thought to regulate C4 (ref. 5), Sekar et al. 4 investigated whether variants in C4 could partially or fully explain this schizophrenia risk locus.
Human C4 is encoded by two genes, C4A and C4B, whose protein products target distinct molecules. A human endogenous retroviral (HERV) element that may function as an enhancer 6 is either present in or absent from the ninth introns of C4A and C4B, resulting in 4 . Careful refinement of the schizophrenia GWAS locus in the MHC revealed that structural alleles of the C4 locus increase schizophrenia risk. These structural alleles increase C4A RNA levels in human brain, which predict a subsequent increase in C3, increasing synaptic pruning. A mouse knockout of C4 demonstrated that C3 levels decreased and synaptic pruning in the visual system was disrupted, which may be consistent with the model whereby an increase in human C4A expression results in increased synaptic pruning in schizophrenia.
Points of potential convergence of other influences that may increase risk for this complex condition, such as environment and other genetic influences, are also indicated.
volume 19 | number 4 | APrIl 2016 nature neuroscience n e w s a n d v i e w s long or short forms of the genes, respectively. In addition to these four structural alleles for C4, humans also differ in the number of copies of each gene and have distinct SNP haplotypes in these genes. Regions containing repetitive elements or variable repeats are notoriously difficult to genotype. Crucially, Sekar et al. 4 developed a method to accurately genotype both the structure and copy number of the C4A and C4B genes. To assess how these aspects of C4A and C4B influence C4 gene expression, they analyzed 674 samples from among 5 regions in 245 postmortem human brains. The investigators found that the RNA expression of C4A and C4B increased proportionally with the number of genic copies, that C4A expression was two to three times higher than that of C4B (controlled for copy number) and that this ratio of C4A to C4B expression increased with copy number of C4-HERV. Having established a model for how both the structure and the copy number of C4A and C4B influence C4 gene expression in the brain, Sekar et al. 4 were able to generate a genetic predictor of C4A and C4B expression without directly assessing RNA levels. Similarly, studying the SNP haplotypes across the MHC in 222 independent chromosomes from 111 unrelated individuals revealed that a given SNP haplotype was usually associated with a characteristic C4 locus structure, enabling the authors to impute the four most common C4 locus structural variants with reasonably high accuracy from SNP genotype data alone. Together, these two strategies enabled the researchers to predict C4 locus structure and subsequently infer C4 expression from the genome-wide SNP data of the Psychiatric Genomics Consortium's ~29,000 schizophrenia cases and ~36,000 controls, which were the basis of the original GWAS findings 3 .
The investigators then examined ~8,000 SNPs in the extended MHC locus, testing the C4 structural alleles, the HLA sequence polymorphisms (imputed) and the C4A and C4B expression levels for their association with schizophrenia. This analysis identified two independent genetic association signals in the MHC: one at the distal end of the extended MHC locus, with associated SNPs spanning ~2 Mb, and the other centered at C4. Interestingly, SNPs within the C4 association peak were associated with schizophrenia risk in proportion to their effects on C4A expression. Controlling for both of these genetic signals revealed another genomewide-significant association peak proximal to MHC, near SYNGAP1.
Evaluating the risk conferred by each C4 allele, the investigators established a ranking for the four common structural alleles, with relative risks for schizophrenia ranging from 1.0 to 1.27. Furthermore, the predicted C4A expression level for each C4 structural allele mirrored the allelic risk, with the highest C4A gene expression predicted in samples carrying the C4 allele with the highest schizophrenia risk. Measurement of C4A RNA expression in brain tissue from 35 patients with schizophrenia and 70 unaffected controls revealed that, as predicted from this genetic finding, C4A expression was higher in brains from patients than in those from controls. The elevation in C4A expression was observed in all five brain regions examined, including the cerebellumwhich, although not a classical schizophreniaassociated brain region, shows evidence of dysfunction in schizophrenia 7 . How the focal cognitive and behavioral abnormalities present in schizophrenia arise from what appears to be a relatively widespread change in gene expression remains to be determined.
In the adolescent and early adult human brain, mature neural circuits are formed through a process of synapse refinement. Previous characterization of brains from patients with schizophrenia identified a reduction in the number of synapses 8 , suggesting that this process is altered in the disease state. Earlier studies have shown that members of the classic complement cascade, of which C4 is a key member, are critical mediators of this synaptic pruning [9] [10] [11] . In the immune system, C4 is known to promote activation of complement component 3 (C3); in the developing mouse brain, C3 can target specific synapses and is required for synapse elimination by microglia 9,10 . Sekar et al. 4 investigated the localization of C4 in the human brain, finding C4-positive neurons and synapses in hippocampal slices. The investigators then studied an available C4 knockout mouse (only one copy of C4 exists in mice) and found that C3 was greatly reduced in the presynaptic terminals of the homozygous deletion mice and that synaptic refinement (as modeled in the retinogeniculate pathway of the visual system) was altered in both the heterozygous and homozygous C4 knockout mice.
The polygenicity of common diseases, such as schizophrenia, poses many challenges to disease modeling and mechanistic studies. In addition to the difficulty of identifying the causal loci tagged by these alleles, even when identified, causal common alleles typically have individually small effect sizes. Thus, most disease models derived from genetic findings are based on rare alleles with large effect sizes. However, investigating large-effect-size mutations in model systems is not necessarily a panacea; a good example is the case of the fragile X gene (FMR1) in autism-spectrum disorder (ASD), where, although a large-effect risk gene has been identified, the development of associated therapeutics has been challenging 12 . Nevertheless, understanding how small-effect-size alleles such as C4A act combinatorially with other risk variants to cause schizophrenia is a major challenge. Furthermore, moving from understanding risk alleles in the population to understanding the specific risk profile of an individual remains a formidable task 1 . However, if these small-effect-size alleles do converge into a shared pathway(s), then it is conceivable that, because of their modifiability either by genetic background or environment, they are more amenable than major risk alleles to drug targeting of key molecules within the pathway.
This study provides an excellent model for the meticulous identification and characterization of causal, small-effect-size, common loci identified in GWAS. This work suggests that excessive dosage of C4 leads to increased postnatal synaptic pruning, providing the first potential mechanism for the previously observed loss of grey matter 13 and reduced numbers of synaptic structures in the neurons of patients with schizophrenia 8 . Importantly, if this aberrant synaptic pruning is critical to disease pathogenesis, then this also raises the question of whether other schizophrenia susceptibility loci found in an individual patient act in the same biological pathway as C4A to affect synaptic pruning, act in multiple distinct pathways leading to increased synaptic pruning or, more complicated still, create vulnerability by limiting the activities of other, potentially compensatory pathways. Certainly, connecting excessive synaptic pruning to schizophrenia pathogenicity by no means proves that this is the only pathogenic mechanism at work in schizophrenia, but it is intriguing to consider whether clinical subtypes can be clustered by their underlying mechanistic origins. Disentangling these possibilities assumes not only that we are able to identify the causal loci themselves, but also that we can recognize and group them into biological pathways once identified. Given that the C4A gene was not previously annotated with a nonimmune function (via gene ontology databases), it is almost certain that many incomplete functional gene annotations exist, and the amount of biological characterization required for each identified gene and gene-gene interaction may be extensive.
Even if a risk gene is functionally annotated and preliminary neurobiology studies have been conducted, a complete understanding of mechanism in the context of disease pathophysiology in humans requires appropriate modeling. To interpret how elevated C4A expression increases schizophrenia npg n e w s a 4 studied the retinogeniculate pathway of the visual system in C4 knockout mice. The most obvious question raised by this approach is whether conclusions drawn from knocking out C4 can be translated to understanding the function of C4 overexpression. In mice, the isotypes of C4A and C4B are encoded by C4 alone; and although sequence similarity suggests parallel function, the implication that C4A dosage alone increases risk in humans is difficult to scrutinize in this model system. Finally, although they are undoubtedly relevant, we have no formal rubric to guide translation of the results obtained from modeling in a primary sensory circuit of a divergent species to synaptic pruning in higher association areas of the human brain that are implicated in schizophrenia.
Furthermore, since synaptic pruning is implicated in other neurological disorders, we need to reach a more refined understanding of which aspects of this process provide disorder specificity. One possibility is that synaptic pruning in these other disorders is caused by perturbation of a pathway other than C4 and that this other pathway shows temporal, spatial or cell type differences. Support for this theory comes from ASD, where synaptic abnormalities have been reported 14 , but preliminary results from the Psychiatric Genomics Consortium's ASD GWAS (unpublished data) show no hint of association in the MHC locus. This preliminary GWAS included ~6,500 ASD cases, a sample size on the same order of magnitude as that with which MHC was detected in schizophrenia 15 , suggesting that ASD synaptic pruning defects are likely not caused by the C4 locus. Given that antipsychotic drugs blocking the dopamine D2 receptor (DRD2) are particularly effective in some schizophrenia patients, one obvious avenue to explore is the possibility that C3-mediated synaptic pruning preferentially targets dopaminergic neurons or the frontal lobe circuits that they project to, and thus clinical responsiveness may also correlate with C4 allele genotype.
Finally, one very important observation is the approximately twofold elevation in concordance for schizophrenia in dizygotic twins as compared to non-twin siblings, which, along with other epidemiological data, implicates shared environmental influences (in addition to genetics) in schizophrenia risk. Given the dosage sensitivity of synaptic pruning to C4 levels and their potential environmental regulation (for example, via maternal infection or immune activation), C4 alleles provide a potential target for gene-environment interactions to modulate risk for schizophrenia by shaping brain circuit development. So, although we still lack a comprehensive view of the pathophysiological basis of schizophrenia, Sekar et al. 4 have taken a major step toward building a solid foundation for understanding of the biological mechanisms leading to schizophrenia and provide hope that such neurobiological understanding will soon catch up to the recent progress in genetics.
Sequencing exomes of patients with schizophrenia has shown that coding mutations contribute to disease risk, but turning that observation into robust gene identification has been hard. Singh et al. 1 use exome sequencing data to implicate SETD1A, a modulator of chromatin, as a cause of psychotic illness. The work highlights the need to screen very large sample sizes to find the rare causative mutations that implicate specific genes.
Geneticists think of complex diseases, such as schizophrenia, as having two distinct genetic origins. One involves variants present in high frequencies in the population. For example, for each common variant there might be a 50% chance that you carry a susceptibility allele. For a condition whose genetic susceptibility arises from hundreds of such variants, you'll almost definitely be carrying some of these. Carrying a single common susceptibility allele increases the risk of disease, but don't worry: it's only by a tiny amount, perhaps 1.01-fold. The second genetic origin involves the contribution of rare variants. Indeed, these variants could be so rare that some are specific to an individual or a family. Some of these variants (at least the ones geneticists dream about finding) have much larger effects than common variants, so that their carriers might have fourfold, tenfold or even larger risks of developing illness.
Although this distinction is artificial (in the sense that the frequencies at which variants occur are not neatly divided into common and rare, but instead exist on a continuum), it is still a useful heuristic. A rare, larger-effect variant can occur within the coding region of a gene, as a single-nucleotide polymorphism (SNP) that changes functionally critical amino acids or leads to premature truncation of the protein. This has two notable consequences: first, it indicates which gene is involved in the disease, and second, it provides a relatively easy target for modeling the disease-for example, by introducing the variant into a mouse, fly or worm. These two features explain why there is such interest in finding rare variants in neuropsychiatric disease 2 .
By contrast, while testing common variants for association with disease in genome-wide association studies (GWAS) has become routine, the genes and associated mechanisms that common variants influence are much more difficult to decipher. For instance, it has npg
